Pfizer CEO points to IRA as a factor that made Seagen an attractive target
One of the reasons Pfizer sought to purchase Seagen, as part of a $43 billion deal announced this morning, is that the Seattle-based biotech will be able to withstand the coming headwinds of the Inflation Reduction Act and the Medicare price negotiations that come with it.
Unlike some of his pharma CEO peers who have lambasted the new law, Pfizer CEO Albert Bourla told investors on a call this morning that there are two specific factors pertaining to the IRA that will actually help with the combo of Pfizer and Seagen moving forward:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.